Evaluation of the efficacy of daclatasvir+asunaprevir+beclabuvir for Japanese hepatitis C patients; a prospective study in real life settings.

Evaluation of the efficacy of daclatasvir+asunaprevir+beclabuvir for Japanese hepatitis C patients; a prospective study in real life settings. - The efficacy of daclatasvir+asunaprevir+beclabuvir for Japanese hepatitis C patients.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026909

Enrollment

100

Registered

2017-04-10

Start date

2017-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cirrhotic and noncirrhotic patients with chronic hepatitis C virus

Interventions

combination tablet of daclatasvir/asunaprevir/beclabuvir (15mg/100mg/37.5mg) two tablets twice daily for 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: chronic hepatitis C and compensated cirrhotic patients with HCV genotype 1b

Exclusion criteria

Exclusion criteria: decompensated cirrhosis

Design outcomes

Primary

Measure	Time frame
sustained virological response (SVR) at 12 week and 24 week after the end of treatment	—

Secondary

Measure	Time frame
incidence rate of adverse events	—

Countries

Japan

Contacts

Public ContactHitomi Sezaki

Toranomon Hospital hepatology

hitomis@mx1.harmonix.ne.jp03-3588-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026